Tissue Therapies claims success in diabetic ulcer study
06 July, 2005 by Helen SchullerA new lab study has shown that Brisbane-based Tissue Therapies' (ASX:TIS) VitroGro technology could stimulate the growth of human skin cells, offering hope for a new treatment for diabetic ulcers, the company said.
NeuroDiscovery to acquire UK firm, list on ASX
05 July, 2005 by Helen SchullerNeuroDiscovery, a Perth-based neurology-focused biotech company, has lodged an IPO prospectus with ASIC to raise funds and acquire 100 per cent of NeuroSolutions, a UK-based service provider and drug discovery company.
Probiotec relocates to Victoria
05 July, 2005 by Helen SchullerProbiotec, which bought Agenix' Milton Pharmaceuticals division earlier this year, has relocated from Brisbane to Victoria.
Mesoblast to establish ADR program
05 July, 2005 by Ruth BeranAdult stem cell company Mesoblast (ASX:MSV), which listed on the ASX six months ago, has appointed the Bank of New York to establish and maintain a Level 1 American Depositary Receipt (ADR) program.
Bone Medical completes Phase I Perthoxal osteoporosis trial
04 July, 2005 by Ruth BeranBone Medical (ASX:BNE) has completed a Phase I trial of its oral parathyroid hormone (PTH) product Perthoxal under development for the treatment of osteoporosis.
Novogen bowel disease drug set to enter Phase I trial
04 July, 2005 by Ruth BeranBiopharmaceutical company Novogen's (ASX:NRT) anti-inflammatory compound NV-52 is set to enter Phase I trials at the Gold Coast Hospital.
CogState sales topped $1m in 2004-05
04 July, 2005 by Ruth BeranMelbourne-based neurodiagnostic specialist CogState (ASX:CGS) says its sales exceeded AUD$1 million in sales for the 2004-05 fiscal year, up 420 per cent on the previous year, largely through sales to major pharmaceutical companies and research institutions.
In brief: Rockeby, GTG, PharmAust, Mimotopes, Solbec
04 July, 2005 by Ruth BeranRockeby Biomed (ASX:RBY) has lodged a prospectus to raise AUD$1.78 million through a non-renounceable one-for-one share rights issue. The issue price for each share is $0.01 and the company expects the capital to see it through to the end of financial year 2006.
BioProspect cops Euro setback
01 July, 2005 by Graeme O'NeillBrisbane natural pesticide developer BioProspect (ASX:BPO) faced a setback this week, after its potential European licensee, Germany's W Neudorff, declined to pursue development of BioProspect's eucalyptus-derived biocide for carpet beetles and clothes moths.
Apollo Life Sciences lists at premium
01 July, 2005 by Ruth BeranSydney-based biopharmaceutical Apollo Life Sciences (ASX:AOP) has made a stellar debut on the ASX, at a 54 per cent premium to its offer price.
Peplin gears up for skin drug trials
30 June, 2005 by Graeme O'NeillBrisbane's Peplin Biotech (ASX:PEP) has enrolled the last of 60 Australian patients for its Phase IIa clinical trial of its topical PEP005 treatment for actinic keratoses (AKs) -- pre-cancerous, dry, scaly areas of sun-damaged skin.
CBio opens new labs, outlines development plans
30 June, 2005 by Graeme O'NeillBrisbane biopharma CBio has broken the proverbial bottle of champagne over the bows of its new laboratory and office premises at Brisbane Technology Park, and with Commonwealth P3 grant in hand, is ready to "forge ahead" with developing its novel anti-inflammatory molecule.
In brief: Prima, SciGen, Sonic
30 June, 2005 by Ruth BeranThe executive director of the Austin Research Institute, Mark Hogarth, has resigned as a director of Prima Biomed (ASX:PRR). The company cited Hogarth's increased responsibilities at the ARI for his resignation.
Avexa back to the drawing board on hepatitis B program
30 June, 2005 by Ruth BeranMelbourne-based biotech Avexa (ASX:AVX) has been forced to rethink its plans to develop its reformulated hepatitis B candidate AVX491.
Progen hires Burrill as PI-88 heads to market
29 June, 2005 by Graeme O'NeillBrisbane cancer-drug developer Progen Industries (ASX:PGL, NASDAQ:PGLAF) has appointed San Francisco's Burrill and Co as matchmaker to sift its crammed dance card for a partner to take its promising angiogenesis inhibitor PI-88 to the market.
